A Multi-Center, Open Label Study to Assess the Safety, Steady-State Pharmacokinetics and Pharmacodynamics of IMG-7289 in Patients With Myelofibrosis

Trial Profile

A Multi-Center, Open Label Study to Assess the Safety, Steady-State Pharmacokinetics and Pharmacodynamics of IMG-7289 in Patients With Myelofibrosis

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Aug 2018

At a glance

  • Drugs IMG 7289 (Primary)
  • Indications Myelofibrosis
  • Focus Adverse reactions
  • Sponsors Imago BioSciences
  • Most Recent Events

    • 08 Aug 2018 Planned End Date changed from 1 Dec 2018 to 1 Feb 2019.
    • 08 Aug 2018 Planned primary completion date changed from 1 Feb 2018 to 31 Dec 2018.
    • 01 Feb 2018 According to an Imago BioSciences media release, the company is planning to expand this trial in United States in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top